457 filings
Page 2 of 23
6-K
hfuc5 fzogaoxgjh
30 Jan 24
HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer
6:17am
6-K
mu1jl7px6k7
11 Jan 24
HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status
6:02am
6-K
luby6o
29 Dec 23
Current report (foreign)
6:04am
6-K
adesco
21 Dec 23
Current report (foreign)
6:14am
6-K
yqotkolwk2ajnmhk5c2
13 Dec 23
Current report (foreign)
6:04am
6-K
rcwjd201yl8azzil
7 Dec 23
Current report (foreign)
6:03am
6-K
x3n783dkj
1 Dec 23
HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology Congresses
6:03am
6-K
o32kcsbp4od
30 Nov 23
Current report (foreign)
6:09am
6-K
z9rewxxygh7 dba
9 Nov 23
HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer
6:03am
6-K
0vce 0nei
24 Oct 23
Vesting of awards under the Long Term Incentive Plan
6:19am
6-K
eaz 1yxnkbe0ym3d6
16 Oct 23
HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2023
6:05am
6-K
uu28xhw ib
29 Sep 23
Current report (foreign)
6:20am
6-K
nivagvb
14 Sep 23
Current report (foreign)
6:14am
6-K
llrasd3psc6
12 Sep 23
HUTCHMED Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China
6:10am
UPLOAD
o9kixxxfwd
12 Sep 23
Letter from SEC
12:00am
6-K
69rdebms
31 Aug 23
Current report (foreign)
6:04am
6-K
lk51cl84eo
29 Aug 23
HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer
6:12am
CORRESP
n76kjeuuqf
24 Aug 23
Correspondence with SEC
12:00am
6-K
fb4lqvk0t3 ded
21 Aug 23
HUTCHMED Announces that the Sovleplenib Phase III ESLIM-01 Study Met Its Primary Endpoint in Primary Immune Thrombocytopenia in China
6:10am
UPLOAD
e01d18a9
10 Aug 23
Letter from SEC
12:00am